MedTrace Logo

Biomarker Development for Muscular Dystrophies

NCT05019625 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2025-11-24

No results posted yet for this study

Summary

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases.

Conditions

Sponsors & Collaborators

  • Boston Children's Hospital

    collaborator OTHER

  • Wake Forest University

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Thurman M. Wheeler, MD · Massachusetts General Hospital

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-20
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019625 on ClinicalTrials.gov